Details of Pfizer’s Investigation Into an Omicron-Specific Vaccine for Adults Aged 18 to 55

Sachin Nagrani, MD, the medical director of Heal, discusses Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

Pharmacy Times interviewed Sachin Nagrani, MD, the medical director of Heal, on Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

During the interview, Nagrani provided details regarding the Pfizer Omicron-specific vaccine under investigation, when the vaccine may become available to be sent to pharmacies for administration to patients, whether Pfizer is the only company looking to develop a specific variant-targeted vaccine, and whether booster shots that are not variant-specific are still beneficial for patients to pursue.